Creative Medical Technology Holdings Inc (CELZ)

[NSX]

$CELZ.....this is where, who, and when The IRB, Investigational Review Board, and conducted/sponsored by Dr. Rajfer demonstrating that this Caverstem procedure is "Safe and effective"

The clinical trial covering patients ages 18 to 80 received Institutional Review Board (IRB) approval in December 2016. The trial is sponsored by us based on our patented technology and is conducted by Dr. Jacob Rajfer, Principal Investigator and Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA.

"I am pleased with the expedience and efficiency at which enrollment was reached. As someone who regularly sees patients suffering from treatment non-responsive erectile dysfunction, I am excited to see the development of a novel approach to treating this condition using the patient's own natural regenerative processes," said Dr. Alexander Gershman, member of the Company's Scientific Advisory Board and Director of Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center."

"We are very fortunate to work with the expert team at Los Angeles Biomedical Institute - UCLA/Harbor Hospital who have done an outstanding job with subject recruitment, screening, treatment and follow-up. We firmly believe that we are on schedule for commercialization of the Caverstem TM procedure through publication and presentation of trial results, marketing, licensing, training and sales in 2018," said Timothy Warbington, President and CEOhttps://www.otcmarkets.com/stock/CELZ/news/Creative-Medical-Technology-Holdings-Achieves-100-Patient-Enrollment-in-CaverstemTM-Clinical-Trial-for-Stem-Cell-Treatme?id=168239 of Creative Medical Technology Holdings Inc.